CONCARLO Holdings, LLC is a precision medicine oncology company, whose goal is to develop novel inhibitors and diagnostics to extend the lives of metastatic breast cancer patients. Our lead IpY is a $2B+ opportunity to treat drug-resistant Breast Cancer by targeting p27Kip1.